- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04112316
Developing Oral LT3 Therapy for Heart Failure - HFrEF (DOT3HF-HFrEF)
September 22, 2023 updated by: Anne Cappola, MD, University of Pennsylvania
Developing Oral LT3 Therapy For Heart Failure With Reduced Ejection Fraction
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with reduced ejection fraction (HFrEF) and low triiothyronine (T3) syndrome by conducting a randomized, double-blind, placebo-controlled cross-over study with a two week washout period between treatments.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The overall goal is to determine the safety, feasibility, and preliminary efficacy of administering oral LT3 therapy in the study population of participants with heart failure with reduced ejection fraction (HFrEF).
Each treatment period will be approximately 8 weeks in duration, with weekly titration of study drug for 4 weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to the other arm (placebo or drug).
LT3 will be titrated to T3 levels.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anne C Holland, BA
- Phone Number: 215-573-0902
- Email: anne.holland@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- PennMedicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Men and women aged ≥18 years
- NYHA Class I, II or III heart failure
- EF≤40 percent within the past year
- An implantable cardioverter-defibrillator (ICD)
- Stable doses of neurohormonal blockade for 30 days
- TSH and free T4 level within the laboratory reference range and total T3 level <94 ng/dL
Exclusion Criteria:
- Hypertrophic or restrictive cardiomyopathy
- Uncorrected severe primary valvular disease
- Arrhythmia that results in irregular heart rate
- Inability to perform VO2max exercise testing
- Severe lung disease, including treatment with oral steroids within past 6 months for exacerbation of obstructive lung disease or use of daytime supplemental oxygen
- Serum creatinine > 3.0 mg/dL
- History of cirrhosis
- LVAD use
- Heart failure hospitalization within past month
- Acute coronary syndrome, coronary intervention or ablation therapy within past 2 months or cardiac surgery, percutaneous repair of a valve or septal defect repair within the past 6 months
- Taking thyroid extract, LT4, LT3, amiodarone, or medication that affects the absorption or metabolism of thyroid hormone; gastrointestinal conditions that affect the absorption of thyroid hormone
- If female, current or planned pregnancy within the timeframe of study participation
- Any medical condition that in the opinion of the investigator, will interfere with the safe completion of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Liothyronine (LT3)
Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation.
Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
|
Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.
|
Placebo Comparator: Placebo
A placebo tablet matching in appearance to LT3 tablets dosed equivalently.
Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
|
Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac Rhythm Monitoring by 14 day Patch Rhythm Assessment
Time Frame: continuous during intervention (14 days)
|
Percent increase (atrial fibrillation, ventricular tachycardia, supraventricular and ventricular) ectopy
|
continuous during intervention (14 days)
|
T3 Level
Time Frame: 8 weeks
|
Percentage of participant T3 levels above upper limit of reference range
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Maximal Rate of Oxygen Consumption During Exercise (VO2 Max)
Time Frame: 8 weeks
|
Change peak rate of oxygen consumption
|
8 weeks
|
Actigraphy
Time Frame: 8 weeks
|
Change in remotely sensed difference in counts per minute (CPM)
|
8 weeks
|
Measure of Quality of Life
Time Frame: 8 weeks
|
Change in Kansas City Cardiomyopathy Questionnaire, KCCQ
|
8 weeks
|
NT-proBNP levels
Time Frame: 8 weeks
|
Change in B-type natriuretic peptide, Pg/mL
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Anne R Cappola, MD,ScM, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 11, 2020
Primary Completion (Actual)
August 31, 2023
Study Completion (Actual)
August 31, 2023
Study Registration Dates
First Submitted
September 30, 2019
First Submitted That Met QC Criteria
September 30, 2019
First Posted (Actual)
October 2, 2019
Study Record Updates
Last Update Posted (Actual)
September 26, 2023
Last Update Submitted That Met QC Criteria
September 22, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 833681r
- 1R61HL146390-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure With Reduced Ejection Fraction
-
University of SienaEuropean Association of Cardiovascular ImagingActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection FractionSpain, Greece, Turkey, Portugal, Australia, Belgium, Italy, Mexico, Netherlands, North Macedonia, Romania, Tunisia
-
Novartis PharmaceuticalsCompletedHeart Failure With Reduced Ejection Fraction (HFrEF) | or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)Netherlands, United States
-
University Hospital, AkershusNovartisActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionNorway
-
Board of Trustees of Illinois State UniversityUniversity of Colorado, Denver; Abbott; University of North Carolina, Greensboro and other collaboratorsRecruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Medical University of South CarolinaCompletedHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Normal Ejection FractionUnited States
-
Milton S. Hershey Medical CenterCompletedHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Milton S. Hershey Medical CenterWithdrawnHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Fondazione Toscana Gabriele MonasterioAzienda Ospedaliera Città della Salute e della Scienza di TorinoNot yet recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Midrange Ejection FractionItaly
-
Massachusetts General HospitalRoche DiagnosticsRecruitingCardiovascular Risk Factor | Heart Failure With Reduced Ejection Fraction | Heart Failure With Normal Ejection Fraction | Heart Failure, Right Sided | Heart Failure With Mid Range Ejection FractionUnited States
-
Occlutech International ABActive, not recruitingHeart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure With Reduced Ejection Fraction (HFrEF)United States
Clinical Trials on liothyronine or placebo
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Failure With Preserved Ejection Fraction | Low Triiodothyronine SyndromeUnited States
-
Northwell HealthNational Alliance for Research on Schizophrenia and DepressionCompleted
-
Jens FaberCompletedHeart Failure | Low T3 SyndromeDenmark
-
Ipe, LLCCompleted
-
Oregon Health and Science UniversityCompletedMultiple SclerosisUnited States
-
Patrice PerronTheramed co.CompletedThyroid CancerCanada
-
Oslo University HospitalHormonlaboratoriet; Spesialistsenteret Pilestredet ParkCompletedEndocrine System Diseases | Hypothyroidism | BiomarkersNorway
-
Ipe, LLCCompleted
-
Azienda USL ModenaCompleted
-
Johns Hopkins UniversityCompletedMultiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary ProgressiveUnited States